Summary

Market Overview:

The North America HIV drugs market size reached US$ 21.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 30.0 Billion by 2028, exhibiting a growth rate (CAGR) of 5.6% during 2023-2028.

HIV, which stands for human immunodeficiency virus, is a type of retrovirus which damages the immune system by destroying the white blood cells, or CD4 cells, that help in fighting against infection. Antiretroviral therapy, or ART, is known as the method used for treating the HIV infection with HIV drugs. ART patients must follow the HIV regimen every day in which they have to consume a prescribed combination of HIV drugs. This therapy method does not cure HIV but, instead, helps people with the infection to lead longer and healthier lives. HIV drugs help in preventing the multiplication of HIV which provides a possible recovery chance to the patients. These drugs make the immune system strong enough to resist certain infections and other HIV-related complications.

North America HIV drugs market is currently being driven by several factors. The region currently represents one of the strongest economies leading to a well-established healthcare system. This acts as one of the key factors which is fostering the growth of the HIV drugs market in the region. In addition to this, the US and Canadian governments are consistently extending their helping-hand by investing funds on the research and development of safer and potent HIV drugs. Moreover, higher diagnosis and treatment rate coupled with a surge in the adoption of advanced treatments act as another factor which is facilitating the growth of the HIV drugs market in North America. Apart from this, Antiretroviral drugs have played a major role in improving survival rates and the quality of life of HIV patients. These drugs help the immune system to keep the levels of the virus to a minimum level and prevent infections, leading to the prolonged life expectancy in patients. Antiretrovirals, when taken in the right combination can result in immune reconstitution, restore health, and prevent the development of AIDS and AIDS-related conditions. The progressive reduction in mortality and gains in the life expectancy are also a result of the improvements in therapy over the past few years. Additionally, antiretroviral drugs help in reducing the risk of HIV transmission. HIV treatment helps in reducing the level of the virus in the blood and other bodily fluids such as semen and vaginal and rectal fluids to imperceptible levels. It also helps in controlling the replication of the virus in the body.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the North America HIV drugs market report, along with forecasts at the regional and country level from 2023-2028. Our report has categorized the market based on drug class and distribution channel.

Key Regions Analysed
United States
Canada

Analysis for Each Country

Market by Drug Class
Nucleoside Reverse Transcriptase Inhibitors
Multi-Class Combination Products
Protease Inhibitors
HIV Integrase Strand Transfer Inhibitors
Non-Nucleoside Reverse Transcriptase Inhibitors
Entry Inhibitors — CCR5 Co-Receptor Antagonist
Others

Market by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Value Chain Analysis
Key Drivers and Challenges
Porters Five Forces Analysis
Competitive Landscape
Competitive Structure
Key Player Profiles

IMARC’s new report provides a deep insight into the North America HIV drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for drug manufacturers, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the North America HIV drugs market in any manner.

Key Questions Answered in This Report:
How has the North America HIV drugs market performed so far and how will it perform in the coming years?
What are the key regions in the North America HIV drugs market?
What has been the impact of COVID-19 on the North America HIV drugs market?
What is the breakup of the North America HIV drugs market on the basis of drug class?
What is the breakup of the North America HIV drugs market on the basis of distribution channel?
What are the various stages in the value chain of the North America HIV drugs industry?
What are the key driving factors and challenges in the North America HIV drugs industry?
What is the structure of the North America HIV drugs industry and who are the key players?
What is the degree of competition in the North America HIV drugs industry?
What are the profit margins in the North America HIV drugs industry?

ページTOPに戻る

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global HIV Drugs Market
5.1 Market Performance
5.2 Market Breakup by Drug Class
5.3 Market Breakup by Distribution Channel
5.4 Market Breakup by Region
5.5 Market Forecast
6 North America HIV Drugs Market
6.1 Market Performance
6.2 Impact of COVID-19
6.3 Market Forecast
7 North America HIV Drugs Market: Breakup by Drug Class
7.1 Nucleoside Reverse Transcriptase Inhibitors
7.2 Multi-Class Combination Products
7.3 Protease Inhibitors
7.4 HIV Integrase Strand Transfer Inhibitors
7.5 Non-Nucleoside Reverse Transcriptase Inhibitors
7.6 Entry Inhibitors — CCR5 Co-Receptor Antagonist
7.7 Others
8 North America HIV Drugs Market: Breakup by Distribution Channel
8.1 Hospital Pharmacies
8.2 Retail Pharmacies
8.3 Online Pharmacies
8.4 Others
9 North America HIV Drugs Market: Breakup by Country
9.1 United States
9.1.1 Historical Market Trends
9.1.2 Market Breakup by Drug Class
9.1.3 Market Breakup by Distribution Channel
9.1.4 Market Forecast
9.2 Canada
9.2.1 Historical Market Trends
9.2.2 Market Breakup by Drug Class
9.2.3 Market Breakup by Distribution Channel
9.2.4 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
11.1 Overview
11.2 Research and Development
11.3 Raw Material Procurement
11.4 Manufacturing
11.5 Marketing
11.6 Distribution
11.7 End-Use
12 Porter’s Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Rivalry
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players

List of Figures

Figure 1: North America: HIV Drugs Market: Major Drivers and Challenges
Figure 2: Global: HIV Drugs Market: Sales Value (in Billion US$), 2017-2022
Figure 3: Global: HIV Drugs Market: Breakup by Drug Class (in %), 2022
Figure 4: Global: HIV Drugs Market: Breakup by Distribution Channel (in %), 2022
Figure 5: Global: HIV Drugs Market: Breakup by Region (in %), 2022
Figure 6: Global: HIV Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 7: North America: HIV Drugs Market: Sales Value (in Billion US$), 2017-2022
Figure 8: North America: HIV Drugs Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 9: North America: HIV Drugs Market: Breakup by Drug Class (in %), 2022
Figure 10: North America: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
Figure 11: North America: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 12: North America: HIV Drugs (Multi-Class Combination Products) Market: Sales Value (in Million US$), 2017 & 2022
Figure 13: North America: HIV Drugs (Multi-Class Combination Products) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 14: North America: HIV Drugs (Protease Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
Figure 15: North America: HIV Drugs (Protease Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 16: North America: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
Figure 17: North America: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 18: North America: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
Figure 19: North America: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 20: North America: HIV Drugs (Entry Inhibitors — CCR5 Co-Receptor Antagonist) Market: Sales Value (in Million US$), 2017 & 2022
Figure 21: North America: HIV Drugs (Entry Inhibitors — CCR5 Co-Receptor Antagonist) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 22: North America: HIV Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2017 & 2022
Figure 23: North America: HIV Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 24: North America: HIV Drugs Market: Breakup by Distribution Channel (in %), 2022
Figure 25: North America: HIV Drugs Market: Sales through Hospital Pharmacies (in Million US$), 2017 & 2022
Figure 26: North America: HIV Drugs Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2023-2028
Figure 27: North America: HIV Drugs Market: Sales through Retail Pharmacies (in Million US$), 2017 & 2022
Figure 28: North America: HIV Drugs Market Forecast: Sales through Retail Pharmacies (in Million US$), 2023-2028
Figure 29: North America: HIV Drugs Market: Sales through Online Pharmacies (in Million US$), 2017 & 2022
Figure 30: North America: HIV Drugs Market Forecast: Sales through Online Pharmacies (in Million US$), 2023-2028
Figure 31: North America: HIV Drugs Market: Sales through Other Distribution Channels (in Million US$), 2017 & 2022
Figure 32: North America: HIV Drugs Market Forecast: Sales through Other Distribution Channels (in Million US$), 2023-2028
Figure 33: North America: HIV Drugs Market: Breakup by Country (in %), 2022
Figure 34: United States: HIV Drugs Market: Sales Value (in Million US$), 2017-2022
Figure 35: United States: HIV Drugs Market: Breakup by Drug Class (in %), 2022
Figure 36: United States: HIV Drugs Market: Breakup by Distribution Channel (in %), 2022
Figure 37: United States: HIV Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 38: Canada: HIV Drugs Market: Sales Value (in Million US$), 2017-2022
Figure 39: Canada: HIV Drugs Market: Breakup by Drug Class (in %), 2022
Figure 40: Canada: HIV Drugs Market: Breakup by Distribution Channel (in %), 2022
Figure 41: Canada: HIV Drugs Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 42: North America: HIV Drugs Industry: SWOT Analysis
Figure 43: North America: HIV Drugs Industry: Value Chain Analysis
Figure 44: North America: HIV Drugs Industry: Porter’s Five Forces Analysis

List of Tables

Table 1: North America: HIV Drugs Market: Key Industry Highlights, 2022 and 2028
Table 2: North America: HIV Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2023-2028
Table 3: North America: HIV Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
Table 4: North America: HIV Drugs Market Forecast: Breakup by Country (in Million US$), 2023-2028
Table 5: North America: HIV Drugs Market: Competitive Structure
Table 6: North America: HIV Drugs Market: Key Players